| Bristol Chiropractic & Acupuncture Inc | |
|
162 South St, Bristol, CT 06010-6505 | |
| (860) 585-9797 | |
| (860) 589-9002 |
| Full Name | Bristol Chiropractic & Acupuncture Inc |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 162 South St, Bristol, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255765525 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | (* (Not Available)) | Primary |
| Provider Name | Paul C Maselli |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1821173014 PECOS PAC ID: 0547238727 Enrollment ID: I20040924000534 |
News Archive
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
A study backs the existence of "healthy schizotypy," in which psychotic experiences do not lead to mental illness.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.
It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
› Verified 9 days ago
| Provider Name | Glen M Palmisano |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1255360855 PECOS PAC ID: 8628084431 Enrollment ID: I20060303000272 |
News Archive
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
A study backs the existence of "healthy schizotypy," in which psychotic experiences do not lead to mental illness.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.
It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
› Verified 9 days ago
| Provider Name | Henry Janczak |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1841627577 PECOS PAC ID: 5597980292 Enrollment ID: I20150710001561 |
News Archive
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
A study backs the existence of "healthy schizotypy," in which psychotic experiences do not lead to mental illness.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.
It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
› Verified 9 days ago
| Provider Name | Justin C Corbelle |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1770005142 PECOS PAC ID: 4183999667 Enrollment ID: I20171010000343 |
News Archive
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
A study backs the existence of "healthy schizotypy," in which psychotic experiences do not lead to mental illness.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.
It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
› Verified 9 days ago
| Provider Name | Saxon Ireland |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1790306694 PECOS PAC ID: 8224457452 Enrollment ID: I20210601000149 |
News Archive
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
A study backs the existence of "healthy schizotypy," in which psychotic experiences do not lead to mental illness.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.
It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bristol Chiropractic & Acupuncture Inc 162 South St, Bristol, CT 06010-6505 Ph: (860) 585-9797 | Bristol Chiropractic & Acupuncture Inc 162 South St, Bristol, CT 06010-6505 Ph: (860) 585-9797 |
News Archive
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
A study backs the existence of "healthy schizotypy," in which psychotic experiences do not lead to mental illness.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.
It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
› Verified 9 days ago
Dr. Richard Paul Saporito, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 665 Terryville Ave, Bristol, CT 06010 Phone: 860-589-1491 Fax: 860-583-3581 | |
Dr. Mitchell Barry Rose, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 281 N Main St, Bristol, CT 06010 Phone: 860-582-6111 Fax: 860-582-5499 | |
Dr. Glen Michael Palmisano, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 162 South St, Suite 1, Bristol, CT 06010 Phone: 860-585-9797 Fax: 860-589-9002 | |
Dr. Deborah C Terry, D.C Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 146 Farmington Ave, Bristol, CT 06010 Phone: 860-560-3285 | |
Dr. David M Spitz, Chiropractor Medicare: Medicare Enrolled Practice Location: 22 Pine St, Suite 216, Bristol, CT 06010 Phone: 860-583-4346 Fax: 860-583-0667 | |
Astrid Aime Baldrich-sanchez, Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 22 Pine St Ste 216, Bristol, CT 06010 Phone: 860-583-4346 Fax: 860-583-0667 |